Amneal Pharmaceuticals, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

AMRX$21.38+0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Cash Flows

	Nine Months Ended September 30,
	2025	2024
Cash flows from operating activities:
Net income (loss)	$78,360	$(53,134)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	174,345	170,061
Unrealized foreign currency gain	(8,606)	(754)
Amortization of debt issuance costs and discount	18,716	22,280
Reclassification of cash flow hedge	(1,713)	(19,618)
Loss on refinancing	31,365	—
Intangible asset impairment charges	22,784	920
Stock-based compensation	23,751	20,558
Inventory provision	59,326	63,611
Other operating charges and credits, net	3,575	(980)
Changes in assets and liabilities:
Trade accounts receivable, net	(110,228)	(134,031)
Inventories	(66,846)	(78,545)
Prepaid expenses, other current assets and other assets	(20,173)	(2,082)
Related party receivables	(830)	(483)
Accounts payable, accrued expenses and other liabilities	2,744	168,879
Related party payables	3,107	20,339
Net cash provided by operating activities	209,677	177,021
Cash flows from investing activities:
Purchases of property, plant and equipment	(48,290)	(36,769)
Acquisition of intangible assets	(12,514)	(14,050)
Deposits for future acquisition of property, plant and equipment	(7,384)	(1,107)
Proceeds from sale of property, plant and equipment	1,379	—
Proceeds from sale of subsidiary	—	4,989
Net cash used in investing activities	(66,809)	(46,937)
Cash flows from financing activities:
Proceeds from issuance of debt	2,694,750	—
Payments of principal on debt, revolving credit facilities, financing leases and other	(2,805,384)	(133,383)
Payments of deferred financing and refinancing costs	(74,973)	—
Borrowings on revolving credit facilities	218,000	48,000
Proceeds from exercise of stock options	1,407	1,003
Employee payroll tax withholding on restricted stock unit and performance stock unit vesting	(21,957)	(7,565)
Tax and other distributions to non-controlling interests	(38,825)	(14,442)
Payment of principal on notes payable - related party	—	(44,200)
Proceeds from alliance party	5,572	—
Net cash used in financing activities	(21,410)	(150,587)
Effect of foreign exchange rate on cash	(1,471)	(259)
Net increase (decrease) in cash, cash equivalents, and restricted cash	119,987	(20,762)
Cash, cash equivalents, and restricted cash - beginning of period	118,420	99,107
Cash, cash equivalents, and restricted cash - end of period	$238,407	$78,345
Cash and cash equivalents - end of period	$201,249	$74,006
Restricted cash - end of period	34,727	4,339
Long-term restricted cash included in other assets - end of period	2,431	—
Cash, cash equivalents, and restricted cash - end of period	$238,407	$78,345

Consolidated Statements of Cash Flows (continued)

	Nine Months Ended September 30,
	2025	2024
Supplemental disclosure of cash flow information:
Cash paid for interest	$156,447	$202,914
Cash paid, net for income taxes	$17,576	$9,056
Supplemental disclosure of non-cash investing and financing activity:
Payable for acquisition of intangible assets	$411	$2,000
Note receivable for sale of subsidiary - related party	$—	$7,177
Loan for land purchase - related party	$482	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.